Agar

Summary

Agar (CHEMBL2108215) is a phase-3 clinical-stage unknown.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108215
Name	Agar
Type	Unknown
Max phase	3

Also known as: Agar, Agar (gracilaria confervoides), Agar (gracilaria gracilis), unspecified, Agar-agar, B1033, Bengal isinglass, Ceylon isinglass, Chinese isinglass, E-406, Echinocaulon acerosus, Echinocaulon spinellum

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
Not specified	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07318896	Not specified	RECRUITING	Effect of Agar/Collagen-based Compounds on Osteoarticular Pain: Randomized Triple-blind Clinical Trial
NCT02012543	Not specified	COMPLETED	Effect of Agar Administration on Defecation and Fecal Condition in Chronic Constipated Patients
NCT02608983	Not specified	COMPLETED	Hydrocolloids as Functional Food Ingredients for Gut Health

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).